var data={"title":"Chronic anticoagulation after acute coronary syndromes","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chronic anticoagulation after acute coronary syndromes</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Gregory YH Lip, MD, FRCPE, FESC, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Freek Verheugt, MD, FACC, FESC</a></dd><dd><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Christopher P Cannon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/contributors\" class=\"contributor contributor_credentials\">Gordon M Saperia, MD, FACC</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 11, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In some patients with an acute coronary syndrome (ACS) (see <a href=\"topic.htm?path=criteria-for-the-diagnosis-of-acute-myocardial-infarction#H3\" class=\"medical medical_review\">&quot;Criteria for the diagnosis of acute myocardial infarction&quot;, section on 'Acute coronary syndrome'</a>), chronic oral anticoagulation is required to lower the risk of systemic (arterial) thromboembolism, such as those with atrial fibrillation, left ventricular systolic dysfunction or thrombus, or prosthetic heart valves. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;</a> and <a href=\"topic.htm?path=antithrombotic-therapy-in-patients-with-heart-failure\" class=\"medical medical_review\">&quot;Antithrombotic therapy in patients with heart failure&quot;</a> and <a href=\"topic.htm?path=antithrombotic-therapy-for-prosthetic-heart-valves-indications\" class=\"medical medical_review\">&quot;Antithrombotic therapy for prosthetic heart valves: Indications&quot;</a> and <a href=\"topic.htm?path=left-ventricular-thrombus-after-acute-myocardial-infarction#H16390947\" class=\"medical medical_review\">&quot;Left ventricular thrombus after acute myocardial infarction&quot;, section on 'Prevention of embolic events'</a>.)</p><p>ACS patients are routinely treated with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and a P2Y<sub>12</sub> receptor blocker (eg, <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>, <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>, or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>) to decrease the risk of recurrent events (See <a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes#H43\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute non-ST elevation acute coronary syndromes&quot;, section on 'Summary and recommendations'</a> and <a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction#H36\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute ST elevation myocardial infarction&quot;, section on 'Summary and recommendations'</a>.) Thus, those who also require oral anticoagulation are discharged on triple oral anticoagulant therapy (TOAT). (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;</a>.)</p><p>The issue of whether chronic anticoagulant therapy reduces the risk of recurrent cardiovascular events, such as myocardial infarction (MI) or cardiac death, after ACS has been evaluated in clinical trials. The rationale for a potential role of chronic anticoagulant therapy in this setting is based on the following two pieces of information:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The high rates of recurrent ischemic events after ACS due, at least in part, to a persistent thrombotic risk within the coronary circulation. This thrombotic risk stems from heightened platelet reactivity, an increase in activity of some or all of the elements of the coagulation cascade, or both. (See <a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">&quot;Overview of hemostasis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The proven efficacy of long-term antithrombotic therapy with dual antiplatelet therapy in reducing recurrent ischemic events in most patients with an ACS. (See <a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">&quot;Overview of the acute management of non-ST elevation acute coronary syndromes&quot;</a> and <a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">&quot;Overview of the acute management of ST-elevation myocardial infarction&quot;</a>.)</p><p/><p>This topic will focus on the potential role of oral anticoagulation to prevent recurrent ischemic events in patients with ACS. The use of chronic anticoagulant therapy in ACS patients who have clear indications for it will be addressed briefly here, but is discussed in detail elsewhere. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">BIOLOGIC PLAUSIBILITY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The rationale for possible benefit from chronic anticoagulant therapy for the prevention of recurrent ischemic events comes in part from the following observations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is an ongoing thrombotic risk that may be due to progressive disease [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/1\" class=\"abstract_t\">1</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There is persistent elevation of markers of thrombin generation for as long as six months after acute coronary syndrome (ACS) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/2\" class=\"abstract_t\">2</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Serial angioscopy of culprit plaques (after myocardial infarction [MI]) shows persistence of thrombus at 1, 6, and 18 months (64, 5, and 12 percent respectively) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=pathology-and-pathogenesis-of-the-vulnerable-plaque\" class=\"medical medical_review\">&quot;Pathology and pathogenesis of the vulnerable plaque&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vulnerable plaques are characterized by repeated plaque micro-ruptures, followed by subclinical thrombosis [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In small angiographic follow-up studies of ACS patients treated with either <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>, lesion progression was significantly reduced in the warfarin group [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/1,5\" class=\"abstract_t\">1,5</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Local synthesis of several functionally active coagulation proteins has been demonstrated in human atherosclerotic lesions. These proteins may be involved in atherogenesis, as indicated by increased thrombi-generating activity in early atherosclerotic lesions [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/4\" class=\"abstract_t\">4</a>].</p><p/><p class=\"headingAnchor\" id=\"H169516629\"><span class=\"h1\">PATIENTS WITHOUT OTHER INDICATIONS FOR CHRONIC ANTICOAGULATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Among the available oral anticoagulants, only <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> has been shown to improve clinical outcomes when added to dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS). Taking into account an important increase in bleeding seen with the use of DAPT plus oral anticoagulant, we suggest adding rivaroxaban to DAPT in patients not at high risk of bleeding (eg, patients &lt;75 years of age and normal renal function). (See <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H624013\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;, section on 'Bleeding risk'</a>.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Warfarin</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>DAPT (<a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and a platelet P2Y<sub>12</sub> receptor blocker) is recommended to most patients after ACS, with or without stent implantation. As there are no studies comparing <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> plus DAPT to DAPT alone or to warfarin plus a single antiplatelet agent, the applicability to current practice of the studies presented below is limited. (See <a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes#H43\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute non-ST elevation acute coronary syndromes&quot;, section on 'Summary and recommendations'</a> and <a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction#H36\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute ST elevation myocardial infarction&quot;, section on 'Summary and recommendations'</a> and <a href=\"topic.htm?path=long-term-antiplatelet-therapy-after-coronary-artery-stenting-in-stable-patients#H1840123222\" class=\"medical medical_review\">&quot;Long-term antiplatelet therapy after coronary artery stenting in stable patients&quot;, section on 'Summary and recommendations'</a>.)</p><p>Keeping this limitation in mind, efficacy and safety outcomes have been evaluated in ACS patients treated with <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> alone, <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> alone, and therapy with both. The available evidence suggests that combined therapy may reduce the risk of ischemic events compared to aspirin alone when the International Normalized Ratio (INR) is strictly maintained between 2 and 3. As combined therapy also increases the risk of bleeding compared to monotherapy, the benefit with warfarin is partially offset. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H1044948811\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Bleeding'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h3\">Meta-analyses</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Two meta-analyses of trials that compared <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> plus <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> to aspirin alone came to a similar conclusion: Among ACS patients at low or intermediate risk for bleeding, the benefits of adding warfarin to aspirin outweigh the bleeding risks <strong>only when the</strong> <strong>attained INR was 2 to 3</strong> [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p>The larger meta-analysis evaluated 14 trials with follow-up from three months to five years and involving over 25,000 patients with an ACS [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/6\" class=\"abstract_t\">6</a>]. When evaluating the findings, it should be kept in mind that two of the major contributing trials, CHAMP and CARS, had median INR less than 2. </p><p>The following findings were noted with <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> compared to aspirin alone:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>No significant difference in the overall risk of major adverse events (all cause death, nonfatal myocardial infarction [MI], and nonfatal thromboembolic stroke).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A significant increase in major bleeding (odds ratio 1.77, 95% CI 1.47-2.13).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In trials with a goal INR of 2.0 to 3.0, combination therapy was associated with a significant reduction in the risk of major adverse events (odds ratio 0.73, 95% CI 0.63-0.84).</p><p/><p class=\"headingAnchor\" id=\"H10160367\"><span class=\"h3\">Randomized trials</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In individual randomized trials included in the meta-analyses, the comparator therapy (<a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>, warfarin plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, or aspirin), the intensity of warfarin therapy, or both has varied [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/6-19\" class=\"abstract_t\">6-19</a>]. The intensity of warfarin therapy has varied from low (INR &le;1.5) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/19\" class=\"abstract_t\">19</a>], to moderate (INR 1.5 to 2.5) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/14,16-18\" class=\"abstract_t\">14,16-18</a>], to high (INR 2.5 to 4.8) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/10-15\" class=\"abstract_t\">10-15</a>]. In addition, the trials varied significantly in the percent of patients with ST elevation MI, non-ST elevation MI, and unstable angina. These differences in trial design limit the ability to compare outcomes from one trial to another.</p><p>The following trials account for most of the patients included in the above meta-analysis. In the first five, the majority of ACS patients had either ST elevation or non-ST elevation MI:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The CHAMP trial randomly assigned 5059 patients to either <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> alone (81 <span class=\"nowrap\">mg/day)</span> or a combination of aspirin (81 <span class=\"nowrap\">mg/day)</span> and <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>, titrated to an INR of 1.5 to 2.5 (mean 1.8) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/17\" class=\"abstract_t\">17</a>]. After a 2.7-year follow-up, there was no difference in mortality (17.3 versus 17.6 percent, respectively), nonfatal infarction (13.1 versus 13.3 percent), or nonfatal stroke (3.5 versus 3.1 percent) between the two groups.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The WARIS II trial randomly assigned 3630 patients to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (160 <span class=\"nowrap\">mg/day)</span> alone, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> alone (target INR 2.8 to 4.2, mean attained INR 2.8), or combination therapy at lower dose (aspirin 75 <span class=\"nowrap\">mg/day</span> and target INR 2.0 to 2.5, mean attained INR 2.2) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/13\" class=\"abstract_t\">13</a>]. After a mean follow-up of four years, the incidence of the combined primary outcome of death, nonfatal reinfarction, or thromboembolic stroke was significantly less with combination therapy compared with aspirin alone (15 versus 20 percent, risk reduction 29 percent) and with warfarin alone compared to aspirin alone (16.7 versus 20.0 percent, risk reduction 19 percent). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The ASPECT-2 trial randomly assigned 999 patients to one of three regimens: low dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (80 <span class=\"nowrap\">mg/day);</span> high intensity oral anticoagulation (target INR 3 to 4, mean attained value 3.2); or low dose aspirin plus moderate intensity anticoagulation (target INR 2 to 2.5, mean attained value 2.4) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/14\" class=\"abstract_t\">14</a>]. At a median follow-up of 12 months, the incidence of the primary end point of MI, stroke, or death was significantly lower in the two <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> groups than in the aspirin alone group (5 versus 5 versus 9 percent, respectively). However, almost 20 percent of the warfarin and combined therapy groups discontinued treatment, and only about 40 percent of patients receiving warfarin remained in the therapeutic range.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The CARS trial randomly assigned 8803 patients to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> 160 mg, <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> 3 mg with aspirin 80 mg, or warfarin 1mg with aspirin 80 mg daily. There was no significant difference in the combined primary outcome of reinfarction, non-fatal ischemic stroke, or cardiovascular death at one year [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The LoWASA study randomly assigned 3300 patients to <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> 1.25 mg plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> 75 mg or aspirin 75 mg daily. After a median follow-up of five years, there was no significant difference in the combined primary outcome of cardiovascular death, reinfarction or stroke (28.1 versus 28.8 percent, respectively) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/20\" class=\"abstract_t\">20</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The international OASIS-2 trial randomly assigned 3712 patients (87 percent had unstable angina) to either oral anticoagulation (target INR of 2.5) in addition to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or aspirin alone [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/21\" class=\"abstract_t\">21</a>]. At five months, patients from countries in which there was good compliance to anticoagulation (INR &ge;2) had a significant reduction in the primary end point of cardiovascular death, MI, or stroke (6.1 versus 8.9 percent, relative risk 0.68, 95% CI 0.48-0.95). No such benefit was seen in patients from countries with poor INR compliance. </p><p/><p>As pointed out in the discussion of the meta-analyses above, the inconsistent outcomes in the above trials may have resulted from either differing intensity of oral anticoagulant therapy or relatively high dropout rates in some. </p><p>Two additional limitations question the applicability of these trials to current practice:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>They were performed before the current era in which the great majority of patients with both non-ST elevation and ST elevation ACS are treated with an early invasive strategy using percutaneous coronary intervention (PCI) with stenting [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/7\" class=\"abstract_t\">7</a>]. (See <a href=\"topic.htm?path=coronary-angiography-and-revascularization-for-unstable-angina-or-non-st-elevation-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction&quot;</a> and <a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-determinants-of-outcome\" class=\"medical medical_review\">&quot;Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>They were performed before the current era in which most patients with an ACS are treated dual antiplatelet therapy with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> plus a platelet P2Y<sub>12</sub> receptor blocker. (See <a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes#H15\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute non-ST elevation acute coronary syndromes&quot;, section on 'Specifics of P2Y12 therapy'</a> and <a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction#H518264847\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute ST elevation myocardial infarction&quot;, section on 'With fibrinolytic therapy'</a>.)</p><p/><p>These two limitations render the evidence of benefit from <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> (when added to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>) demonstrated in the meta-analyses above applicable to only a small portion of patients with ACS, as most individuals receive dual antiplatelet therapy and many receive revascularization.</p><p class=\"headingAnchor\" id=\"H169516837\"><span class=\"h2\">Dabigatran</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=dabigatran-drug-information\" class=\"drug drug_general\">Dabigatran</a> is a direct thrombin inhibitor that has been approved for use for the prevention and treatment of venous and arterial thromboembolic disorders. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization#H5\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;, section on 'Select an anticoagulant'</a> and <a href=\"topic.htm?path=venous-thromboembolism-anticoagulation-after-initial-management#H276144205\" class=\"medical medical_review\">&quot;Venous thromboembolism: Anticoagulation after initial management&quot;, section on 'Direct thrombin and factor Xa inhibitors'</a>.)</p><p><a href=\"topic.htm?path=dabigatran-drug-information\" class=\"drug drug_general\">Dabigatran</a> has not been evaluated for efficacy in the setting of ACS and thus we do not recommend its use. With regard to safety, the phase II RE-DEEM trial randomly assigned 1861 MI patients on DAPT to dabigatran or placebo. There was a significant dose-dependent increase in the risk of major or clinically relevant minor bleeding during the six-month treatment period [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/22\" class=\"abstract_t\">22</a>]. </p><p class=\"headingAnchor\" id=\"H10157309\"><span class=\"h2\">Apixaban</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=apixaban-drug-information\" class=\"drug drug_general\">Apixaban</a> is an oral factor Xa inhibitor that has been studied for the prevention of venous thromboembolism in postoperative patients and prevention of systemic embolic events in patients with atrial fibrillation (AF). (See <a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects#H21\" class=\"medical medical_review\">&quot;Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects&quot;, section on 'Apixaban'</a> and <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;</a> and <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization#H5\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;, section on 'Select an anticoagulant'</a>.)</p><p>The APPRAISE-2 trial, which randomly assigned 7392 patients with an ACS to either <a href=\"topic.htm?path=apixaban-drug-information\" class=\"drug drug_general\">apixaban</a> 5 mg twice daily or placebo in addition to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or dual antiplatelet therapy, was stopped early due to a significant increase in the rate of major bleeding in the apixaban group [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/23\" class=\"abstract_t\">23</a>]. Patients included those with either MI or unstable angina (19 percent) within the previous seven days and at least two high-risk features for a recurrent event (age &ge;65 years, diabetes mellitus, MI within five years, history of either cerebrovascular or peripheral artery disease, heart failure or a left ventricular ejection fraction &lt;40 percent, impaired renal function, or no revascularization for the index event). </p><p>At a median follow-up of 241 days, the primary end point of cardiovascular death, MI, or ischemic stroke occurred in a similar percent of patients in the <a href=\"topic.htm?path=apixaban-drug-information\" class=\"drug drug_general\">apixaban</a> and placebo groups (7.5 versus 7.9, respectively), while the primary safety outcome of Thrombolysis in MI (TIMI) major bleeding occurred significantly more often in the group that received apixaban (1.3 versus 0.5 percent) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/24\" class=\"abstract_t\">24</a>]. These findings were consistent in all subgroups, including those stratified by use of revascularization (55 percent of patients underwent medical management without revascularization).</p><p class=\"headingAnchor\" id=\"H3770019\"><span class=\"h2\">Rivaroxaban</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">Rivaroxaban</a> is an oral factor Xa inhibitor that has been rigorously studied for the prevention of systemic embolic events in patients with AF. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;</a> and <a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects#H20\" class=\"medical medical_review\">&quot;Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects&quot;, section on 'Rivaroxaban'</a> and <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization#H5\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;, section on 'Select an anticoagulant'</a>.)</p><p>We believe adding <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> to DAPT in patients with ACS who are not at high risk of bleeding is a reasonable strategy. This recommendation is based on an approximate 1.5 percent absolute decrease in the rate of death balanced against an approximate 1.2 percent absolute increase in major bleeding with the 2.5 mg dose seen in ATLAS 2 ACS-TIMI 51. After the publication of ATLAS 2 ACS-TIMI 51, we did not make a recommendation regarding rivaroxaban, as the 2.5 mg dose was not, and is not, available in the United States. </p><p>The ATLAS 2 ACS-TIMI 51 trial randomly assigned 15,526 patients with recent ACS to either twice-daily doses of either 2.5 mg or 5 mg (&quot;very low&quot; and &quot;low dose&quot;) of <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> or placebo [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/25\" class=\"abstract_t\">25</a>]. These doses are one-quarter and one-half of the full anticoagulation dose. Patients with prior ischemic stroke or transient ischemic attack were excluded from the study. </p><p>All patients were intended to receive DAPT with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and either <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> or <a href=\"topic.htm?path=ticlopidine-united-states-not-available-drug-information\" class=\"drug drug_general\">ticlopidine</a> (<a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a> and <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> were not prescribed); 93 percent of patients ultimately received DAPT. The primary efficacy end point was a composite of death from cardiovascular causes, MI, or stroke. Approximately 50 percent of patients had ST elevation MI (STEMI), 25 percent non-ST elevation MI (NSTEMI), and 25 percent unstable angina. Less than 10 percent of patients were over the age of 75 years. More than 75 percent of patients had normal renal function.</p><p>The following outcomes (comparing drug to placebo) were seen after a mean duration of treatment of 13.1 months:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">Rivaroxaban</a> (both doses combined) significantly reduced the rate of primary efficacy end point (8.9 versus 10.7 percent; hazard ratio [HR] 0.84, 95% CI 0.74-0.96). These rates for the 2.5 and 5 mg doses of rivaroxaban were 9.1 and 8.8 percent, respectively.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The rates of death of cardiovascular cause or any cause were significantly reduced with the 2.5 mg dose (2.7 versus 4.1 and 2.9 versus 4.5 percent, respectively). This survival benefit was not seen with the 5 mg dose. Both doses of <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> significantly reduced the rate of stent thrombosis by about 31 percent.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">Rivaroxaban</a> significantly increased the rate of TIMI major bleeding not related to coronary artery bypass grafting (2.1 versus 0.6 percent; HR 3.96, 95% CI 2.46-6.38). These rates for the 2.5 and 5 mg doses of rivaroxaban were 1.8 and 2.4 percent, respectively. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">Rivaroxaban</a>, compared to placebo, significantly increased the rate of intracranial hemorrhage (0.6 versus 0.2 percent, respectively). The rates for the 2.5 and 5 mg doses were 0.4 and 0.7 percent. There was no significant increase in fatal bleeding (0.3 versus 0.2 percent, respectively); the rates for the 2.5 and 5 mg doses were 0.1 and 0.4 percent, respectively.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among the 7817 patients with STEMI, <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> reduced the primary efficacy end point (8.4 versus 10.6 percent; HR 0.81, 95% CI 0.67-0.97) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/26\" class=\"abstract_t\">26</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among the 9631 patients who underwent PCI and had at least one stent placed, <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> reduced the risk of Academic Research Consortium defined definite or probable stent thrombosis (1.5 versus 1.9 percent; hazard ratio 0.65, 95% CI 0.46-0.93) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/27\" class=\"abstract_t\">27</a>]. </p><p/><p><a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">Rivaroxaban</a>, particularly at the 2.5 mg twice daily dose, appears to improve outcomes in patients with recent ACS when added to DAPT. It should be kept in mind that the level of anticoagulation achieved with either the 2.5 or 5 mg twice daily dose is less than that seen with the 15 or 20 mg once daily dose, as is used in patients with AF. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization#H5\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;, section on 'Select an anticoagulant'</a>.) </p><p>The findings in the ATLAS 2 ACS-TIMI 51 trial were somewhat unexpected given the increase in the rate of major bleeding with full-dose <a href=\"topic.htm?path=apixaban-drug-information\" class=\"drug drug_general\">apixaban</a> in the APPRAISE-2 trial. (See <a href=\"#H10157309\" class=\"local\">'Apixaban'</a> above.) Possible explanations for the difference in bleeding outcomes between the two trials are the inclusion of higher risk patients in APPRAISE-2, including more individuals with prior stroke, and the use of a higher dose of apixaban.</p><p>Two randomized trials of antithrombotic therapy in stable, anticoagulated patients who underwent percutaneous coronary intervention with stenting (WOEST and GEMINI-ACS-1) have suggested that antithrombotic therapy with an anticoagulant plus a P2Y<sub>12</sub> receptor blocker (<a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> omitted) does not cause a significant increase in ischemic events and is associated with a lower risk of major bleeding compared with triple antithrombotic therapy [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/28,29\" class=\"abstract_t\">28,29</a>]. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H2\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Efficacy and safety studies'</a> and <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H2492969741\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Anticoagulant specifics'</a>.) The GEMINI-ACS-1 trial randomly assigned 3037 ACS patients to either aspirin 100 mg daily or <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> 2.5 mg twice daily within 10 days of hospitalization; both groups had received aspirin plus a P2Y12 receptor blocker (<a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>) and both groups continued after randomization with the latter [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/30\" class=\"abstract_t\">30</a>]. After a median treatment duration of 291 days, Thrombolysis in Myocardial Infarction (TIMI) non-coronary artery bypass graft clinically significant bleeding was similar in the two groups (5 percent; hazard ratio 1.09, 95% CI 0.80-1.50, respectively). The study was not powered to assess efficacy. The results of GEMINI-ACS-1 do not change any of the recommendations in this topic.</p><p><a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">Rivaroxaban</a> at the 2.5 mg dose was approved by the European Medicines Agency in March of 2013 for secondary prevention after stabilized ACS in patients who had positive biomarkers at the index event [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/31\" class=\"abstract_t\">31</a>]. The United States Food and Drug Administration&rsquo;s Cardiovascular and Renal Drugs Advisory Committee has voted against approval of rivaroxaban (to reduce the risk of recurrent cardiovascular events in ACS patients or to prevent stent thrombosis in patients with ACS) [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/32,33\" class=\"abstract_t\">32,33</a>]. </p><p class=\"headingAnchor\" id=\"H7962934\"><span class=\"h2\">Summary</span></p><p class=\"headingAnchor\" id=\"H15760471\"><span class=\"h3\">Patients taking dual antiplatelet therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> 2.5 mg twice daily for about one year for ACS patients taking <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> 75 mg daily who are not at high bleeding risk (including those with prior stroke or transient ischemic attack) and who do not have other indications for chronic anticoagulant therapy [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/34\" class=\"abstract_t\">34</a>]. This recommendation does not apply to patients treated with aspirin and either <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>. (See <a href=\"#H3770019\" class=\"local\">'Rivaroxaban'</a> above.) </p><p>High-risk (of bleeding) ACS patients on <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> should not receive <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> if one of the following are present: age &gt;75 years, history of stroke or gastrointestinal bleeding, hepatic or renal disease, malignancy, or excessive fall risk. Other factors such as baseline anemia or hypertension are relative contraindications that become absolute as their severity worsens. We are uncertain as to how to properly identify which moderate bleeding risk patients might benefit from rivaroxaban. Practitioners should have a detailed discussion about the relative benefits and risks of adding rivaroxaban to DAPT with potential candidates. A larger discussion of anticoagulant bleeding and risk factors is found elsewhere. (See <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H624013\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;, section on 'Bleeding risk'</a>.)</p><p>Some ACS patients will not receive dual antiplatelet therapy (DAPT), usually due to allergy to either <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or platelet P2Y<sub>12</sub> receptor blocker. We suggest referral to a specialist (often an allergist) familiar with the management of these patients. There are several types of aspirin hypersensitivity syndromes, which can usually be distinguished by the nature of the patient&rsquo;s past reactions and the presence of certain characteristic underlying conditions (eg, chronic urticaria,&nbsp;asthma, chronic sinus disease). The different types of aspirin hypersensitivity and desensitizations protocols are reviewed separately. (See <a href=\"topic.htm?path=nsaids-including-aspirin-allergic-and-pseudoallergic-reactions#H15\" class=\"medical medical_review\">&quot;NSAIDs (including aspirin): Allergic and pseudoallergic reactions&quot;, section on 'Management'</a> and <a href=\"topic.htm?path=diagnostic-challenge-and-desensitization-protocols-for-nsaid-reactions\" class=\"medical medical_review\">&quot;Diagnostic challenge and desensitization protocols for NSAID reactions&quot;</a> and <a href=\"topic.htm?path=aspirin-exacerbated-respiratory-disease\" class=\"medical medical_review\">&quot;Aspirin-exacerbated respiratory disease&quot;</a> and <a href=\"topic.htm?path=antithrombotic-therapy-for-elective-percutaneous-coronary-intervention-general-use#H15702928\" class=\"medical medical_review\">&quot;Antithrombotic therapy for elective percutaneous coronary intervention: General use&quot;, section on 'Problems with clopidogrel use'</a>.)</p><p class=\"headingAnchor\" id=\"H15760465\"><span class=\"h3\">Patients not taking a platelet P2Y12 receptor blocker</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who cannot receive DAPT with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> plus platelet P2Y<sub>12</sub> receptor blocker, such as those who are allergic to one or both, we make the following recommendations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For those patients who cannot take a platelet P2Y<sub>12</sub> receptor blocker and those in whom the risk of bleeding (<a href=\"image.htm?imageKey=HEME%2F75259\" class=\"graphic graphic_table graphicRef75259 \">table 1</a>) due to long-term therapy with both antiplatelet and anticoagulant drugs is acceptable (see <a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr#H624013\" class=\"medical medical_review\">&quot;Management of warfarin-associated bleeding or supratherapeutic INR&quot;, section on 'Bleeding risk'</a>), we believe the addition of oral anticoagulant to <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> is reasonable. This is based on a possible benefit from such therapy, as demonstrated in the meta-analyses discussed above in those patients in whom the INR on <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> therapy can be consistently between 2.0 and 3.0. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>When therapy with <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> is chosen after ACS, warfarin should be stopped at one year (unless there is another indication for warfarin, such as AF), as the patient is then considered to have stable coronary heart disease. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For the uncommon patient who cannot take <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, options for antithrombotic therapy include a P2Y<sub>12</sub> receptor blocker alone or in combination with an oral anticoagulant. Our authors and reviewers recommend, based on their experience, a potent P2Y<sub>12</sub> receptor blocker (<a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>) alone or <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> plus <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> in combination for these patients. They have a preference for the former for the following reasons:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Potent P2Y<sub>12</sub> monotherapy avoids the inconvenience of routine INR monitoring.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>As P2Y<sub>12</sub> receptor blockers are more effective at reducing the risk of cardiovascular events than <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (see <a href=\"topic.htm?path=aspirin-for-the-secondary-prevention-of-atherosclerotic-cardiovascular-disease#H2710448353\" class=\"medical medical_review\">&quot;Aspirin for the secondary prevention of atherosclerotic cardiovascular disease&quot;, section on 'Alternatives to aspirin'</a>), they do not feel compelled to add <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> for efficacy as in patients who cannot take P2Y<sub>12</sub> inhibitors as discussed above.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Our authors and reviewers do not use <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> plus <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a> in this situation as this combination likely has a greater risk of bleeding compared to warfarin plus <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>.</p><p/><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">PATIENTS WITH INDICATIONS FOR CHRONIC ANTICOAGULATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients with acute coronary syndrome (ACS) require oral anticoagulation (OAC) for other reasons, such as atrial fibrillation, left ventricular thrombus or aneurysm, prosthetic heart valve, or venous thromboembolism. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;</a> and <a href=\"topic.htm?path=left-ventricular-thrombus-after-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Left ventricular thrombus after acute myocardial infarction&quot;</a> and <a href=\"topic.htm?path=left-ventricular-aneurysm-and-pseudoaneurysm-following-acute-myocardial-infarction\" class=\"medical medical_review\">&quot;Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction&quot;</a> and <a href=\"topic.htm?path=antithrombotic-therapy-for-prosthetic-heart-valves-indications\" class=\"medical medical_review\">&quot;Antithrombotic therapy for prosthetic heart valves: Indications&quot;</a> and <a href=\"topic.htm?path=venous-thromboembolism-initiation-of-anticoagulation-first-10-days\" class=\"medical medical_review\">&quot;Venous thromboembolism: Initiation of anticoagulation (first 10 days)&quot;</a>.)</p><p>As most patients with ACS are discharged on <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and a P2Y<sub>12</sub> receptor blocker (eg, <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a>, <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a>, or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>), patients who require OAC may be discharged on triple oral antithrombotic therapy (TOAT). It is important to note that trials of TOAT used clopidogrel, but not ticagrelor or prasugrel. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1831433\"><span class=\"h2\">Stented patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The available evidence supports the use of TOAT, as opposed to dual antiplatelet therapy (DAPT) or to OAC plus a single antiplatelet agent, to decrease the risk of major adverse cardiovascular events in patients with ACS who have undergone intracoronary stenting and who have an indication for chronic oral anticoagulant therapy. This topic is discussed in detail elsewhere. (see <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H2\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Efficacy and safety studies'</a>). </p><p class=\"headingAnchor\" id=\"H1831439\"><span class=\"h2\">Non-stented patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with ACS who have been managed without intracoronary stenting (medical management, fibrinolytic therapy, or coronary artery bypass graft surgery), we prefer <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and an oral anticoagulant to any other thrombotic regimen. After one year, we suggest OAC without antiplatelet therapy. </p><p>There are no prospective studies of OAC plus one antiplatelet agent compared with TOAT in non-stented ACS patients who require OAC. The rationale for our recommendation is the relatively modest reduction in the rate of myocardial infarction seen with the addition of <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> (DAPT) compared with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> alone in the CURE trial, and the evidence that OAC may add to the efficacy of aspirin alone in patients (on <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a>) whose international normalized ratio is kept in the 2.0 to 3.0 range. (See <a href=\"#H4\" class=\"local\">'Meta-analyses'</a> above.)</p><p>For patients who are at low risk of bleeding &#160;and are particularly concerned about recurrent ischemic events, TOAT is a reasonable option. The long-term approach to such patients is presented below. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H3941922365\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Long-term management'</a>.)</p><p>Some evidence of benefit from TOAT in this population comes from studies of <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> and ximelagatran [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/35\" class=\"abstract_t\">35</a>]. (See <a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects\" class=\"medical medical_review\">&quot;Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects&quot;</a>.)</p><p>DAPT is less effective in preventing stroke than OAC; OAC plus <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (without thienopyridine) is insufficient to prevent stent thrombosis [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/36\" class=\"abstract_t\">36</a>]. (See <a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization#H124800782\" class=\"medical medical_review\">&quot;Atrial fibrillation: Anticoagulant therapy to prevent embolization&quot;, section on 'Potential alternatives to anticoagulant monotherapy'</a> and <a href=\"topic.htm?path=long-term-antiplatelet-therapy-after-coronary-artery-stenting-in-stable-patients#H406428135\" class=\"medical medical_review\">&quot;Long-term antiplatelet therapy after coronary artery stenting in stable patients&quot;, section on 'Duration'</a>.)</p><p>Patients who have had an ACS are considered to have stable coronary artery disease after one year and thus have no clear indication for prolonged DAPT. We suggest not routinely adding <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> (or other antiplatelet agent) to OAC to reduce the risk of ischemic cardiovascular disease events in patients with or at high risk for cardiovascular disease who have not been stented. There is no convincing evidence of benefit and the risk of major bleeding with combined therapy is higher. This issue is discussed in detail elsewhere. (See <a href=\"topic.htm?path=aspirin-for-the-secondary-prevention-of-atherosclerotic-cardiovascular-disease\" class=\"medical medical_review\">&quot;Aspirin for the secondary prevention of atherosclerotic cardiovascular disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">RECOMMENDATIONS OF OTHERS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We generally agree with recommendations made in the 2013 American College of Cardiology <span class=\"nowrap\">Foundation/American</span> Heart Association <span class=\"nowrap\">(ACCF/AHA)</span> guidelines on ST-Elevation myocardial infarction and the 2012 focused update on Unstable <span class=\"nowrap\">Angina/Non-ST-Elevation</span> MI as well as the American College of Chest Physicians (ACCP) in the 2012 guideline on the primary and secondary prevention of cardiovascular disease [<a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/37-40\" class=\"abstract_t\">37-40</a>]. </p><p class=\"headingAnchor\" id=\"H22846480\"><span class=\"h1\">BLEEDING RISK</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients who require oral anticoagulant plus antiplatelet (<a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> <span class=\"nowrap\">and/or</span> P2Y<sub>12</sub> receptor blocker) therapy, the bleeding risk is increased significantly compared to either therapy alone. This issue is discussed in detail separately. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H1044948811\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Bleeding'</a>.)</p><p class=\"headingAnchor\" id=\"H3836021848\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-non-st-elevation-acute-coronary-syndromes-non-st-elevation-myocardial-infarction\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Non-ST elevation acute coronary syndromes (non-ST elevation myocardial infarction)&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-st-elevation-myocardial-infarction-stemi\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: ST elevation myocardial infarction (STEMI)&quot;</a> and <a href=\"topic.htm?path=society-guideline-links-anticoagulation\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Anticoagulation&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topic (see <a href=\"topic.htm?path=warfarin-coumadin-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Warfarin (Coumadin) (Beyond the Basics)&quot;</a>) </p><p/><p class=\"headingAnchor\" id=\"H10157891\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most acute coronary syndrome (ACS) patients are treated with dual antiplatelet therapy (DAPT), irrespective of whether an intracoronary stent was placed (See <a href=\"topic.htm?path=antithrombotic-therapy-for-elective-percutaneous-coronary-intervention-general-use#H35\" class=\"medical medical_review\">&quot;Antithrombotic therapy for elective percutaneous coronary intervention: General use&quot;, section on 'Summary and recommendations'</a> and <a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes#H43\" class=\"medical medical_review\">&quot;Antiplatelet agents in acute non-ST elevation acute coronary syndromes&quot;, section on 'Summary and recommendations'</a>.). </p><p>Some of these patients require chronic anticoagulation to lower the risk of systemic thromboembolism (such as those with atrial fibrillation). Recommendations for the use of triple oral antithrombotic therapy are discussed elsewhere. (See <a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy#H24\" class=\"medical medical_review\">&quot;Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy&quot;, section on 'Summary and recommendations'</a>.)</p><p>For ACS patients who do not have an indication (other than an acute ACS) for chronic anticoagulant therapy, we make the following recommendations regarding the addition of oral anticoagulant therapy to antiplatelet therapy to reduce the risk of subsequent ischemic events after an ACS (see <a href=\"#H169516629\" class=\"local\">'Patients without other indications for chronic anticoagulation'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients taking DAPT with low dose <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> and <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> 75 mg daily, we suggest adding <a href=\"topic.htm?path=rivaroxaban-drug-information\" class=\"drug drug_general\">rivaroxaban</a> 2.5 mg twice daily if there are no risk factors for bleeding present (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). The duration of therapy is approximately one year, as studied in the randomized trial. Patients may reasonably choose to not take rivaroxaban if they are particularly concerned about the bleeding risk. This recommendation does not apply to patients taking either <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> or <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a>. (See <a href=\"#H3770019\" class=\"local\">'Rivaroxaban'</a> above and <a href=\"#H7962934\" class=\"local\">'Summary'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A few ACS patients may appear to not be candidates for DAPT due to allergy to either <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> or platelet P2Y<sub>12</sub> receptor blocker. These patients should be referred to a specialist (often an allergist) for an attempt at desensitization. For these<strong> </strong>patients taking antiplatelet monotherapy, we make the following recommendations:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients taking <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a> but unable to take a P2Y<sub>12</sub> receptor blocker and who are at low to intermediate bleeding risk (<a href=\"image.htm?imageKey=HEME%2F75259\" class=\"graphic graphic_table graphicRef75259 \">table 1</a>), we suggest adding <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> to aspirin monotherapy for one year (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). This recommendation applies only if the International Normalized Ratio (INR) can be maintained within the range of 2.0 to 3.0. (See <a href=\"#H7962934\" class=\"local\">'Summary'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients taking P2Y<sub>12</sub> receptor blocker but who are unable to take <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>,<strong> </strong>we suggest antithrombotic monotherapy with either <a href=\"topic.htm?path=ticagrelor-drug-information\" class=\"drug drug_general\">ticagrelor</a> or <a href=\"topic.htm?path=prasugrel-drug-information\" class=\"drug drug_general\">prasugrel</a> (no oral anticoagulant added to either) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>).<strong> </strong>In patients for whom ticagrelor and prasugrel are not available, <a href=\"topic.htm?path=clopidogrel-drug-information\" class=\"drug drug_general\">clopidogrel</a> plus <a href=\"topic.htm?path=warfarin-drug-information\" class=\"drug drug_general\">warfarin</a> is a reasonable alternative.<strong> </strong>(See <a href=\"#H7962934\" class=\"local\">'Summary'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/1\" class=\"nounderline abstract_t\">Williams MJ, Morison IM, Parker JH, Stewart RA. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997; 30:364.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/2\" class=\"nounderline abstract_t\">Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90:61.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/3\" class=\"nounderline abstract_t\">Ueda Y, Asakura M, Yamaguchi O, et al. The healing process of infarct-related plaques. Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 2001; 38:1916.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/4\" class=\"nounderline abstract_t\">Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N Engl J Med 2011; 364:1746.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/5\" class=\"nounderline abstract_t\">Williams MJ, Stewart RA. Coronary artery flow ten weeks after myocardial infarction or unstable angina: effects of combined warfarin and aspirin therapy. Int J Cardiol 1999; 69:19.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/6\" class=\"nounderline abstract_t\">Andreotti F, Testa L, Biondi-Zoccai GG, Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 2006; 27:519.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/7\" class=\"nounderline abstract_t\">Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143:241.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/8\" class=\"nounderline abstract_t\">E.P.S.I.M. Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982; 307:701.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/9\" class=\"nounderline abstract_t\">Breddin K, Loew D, Lechner K, et al. The German-Austrian aspirin trial: a comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. On behalf of the German-Austrian Study Group. Circulation 1980; 62:V63.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/10\" class=\"nounderline abstract_t\">Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Lancet 1994; 343:499.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/11\" class=\"nounderline abstract_t\">Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990; 323:147.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/12\" class=\"nounderline abstract_t\">A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. Lancet 1980; 2:989.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/13\" class=\"nounderline abstract_t\">Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347:969.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/14\" class=\"nounderline abstract_t\">van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002; 360:109.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/15\" class=\"nounderline abstract_t\">Meijer A, Verheugt FW, Werter CJ, et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. Circulation 1993; 87:1524.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/16\" class=\"nounderline abstract_t\">Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ 1996; 313:1429.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/17\" class=\"nounderline abstract_t\">Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation 2002; 105:557.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/18\" class=\"nounderline abstract_t\">Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. Circulation 2002; 106:659.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/19\" class=\"nounderline abstract_t\">Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Lancet 1997; 350:389.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/20\" class=\"nounderline abstract_t\">Herlitz J, Holm J, Peterson M, et al. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study. Eur Heart J 2004; 25:232.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/21\" class=\"nounderline abstract_t\">Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. J Am Coll Cardiol 2001; 37:475.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/22\" class=\"nounderline abstract_t\">Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011; 32:2781.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/23\" class=\"nounderline abstract_t\">Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011; 365:699.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/24\" class=\"nounderline abstract_t\">Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/25\" class=\"nounderline abstract_t\">Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366:9.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/26\" class=\"nounderline abstract_t\">Mega JL, Braunwald E, Murphy SA, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol 2013; 61:1853.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/27\" class=\"nounderline abstract_t\">Gibson CM, Chakrabarti AK, Mega J, et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol 2013; 62:286.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/28\" class=\"nounderline abstract_t\">Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375:2423.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/29\" class=\"nounderline abstract_t\">Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381:1107.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/30\" class=\"nounderline abstract_t\">Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet 2017.</a></li><li class=\"breakAll\">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/smops/Positive/human_smop_000493.jsp&amp;mid=WC0b01ac058001d127.</li><li class=\"breakAll\">http://www.medscape.com/viewarticle/764433?src=mp&amp;spon=2.</li><li class=\"breakAll\">http://www.prnewswire.com/news-releases/fda-issues-complete-response-letter-for-xarelto-rivaroxaban-to-reduce-the-risk-of-stent-thrombosis-in-patients-with-acute-coronary-syndrome-213480081.html.</li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/34\" class=\"nounderline abstract_t\">Kom&oacute;csi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:1537.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/35\" class=\"nounderline abstract_t\">Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009; 374:29.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/36\" class=\"nounderline abstract_t\">Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35:3155.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/37\" class=\"nounderline abstract_t\">2012 Writing Committee Members, Jneid H, Anderson JL, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126:875.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/38\" class=\"nounderline abstract_t\">Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/39\" class=\"nounderline abstract_t\">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:529.</a></li><li><a href=\"https://www.uptodate.com/contents/chronic-anticoagulation-after-acute-coronary-syndromes/abstract/40\" class=\"nounderline abstract_t\">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 101 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H10157891\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">BIOLOGIC PLAUSIBILITY</a></li><li><a href=\"#H169516629\" id=\"outline-link-H169516629\">PATIENTS WITHOUT OTHER INDICATIONS FOR CHRONIC ANTICOAGULATION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Warfarin</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">- Meta-analyses</a></li><li><a href=\"#H10160367\" id=\"outline-link-H10160367\">- Randomized trials</a></li></ul></li><li><a href=\"#H169516837\" id=\"outline-link-H169516837\">Dabigatran</a></li><li><a href=\"#H10157309\" id=\"outline-link-H10157309\">Apixaban</a></li><li><a href=\"#H3770019\" id=\"outline-link-H3770019\">Rivaroxaban</a></li><li><a href=\"#H7962934\" id=\"outline-link-H7962934\">Summary</a><ul><li><a href=\"#H15760471\" id=\"outline-link-H15760471\">- Patients taking dual antiplatelet therapy</a></li><li><a href=\"#H15760465\" id=\"outline-link-H15760465\">- Patients not taking a platelet P2Y12 receptor blocker</a></li></ul></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">PATIENTS WITH INDICATIONS FOR CHRONIC ANTICOAGULATION</a><ul><li><a href=\"#H1831433\" id=\"outline-link-H1831433\">Stented patients</a></li><li><a href=\"#H1831439\" id=\"outline-link-H1831439\">Non-stented patients</a></li></ul></li><li><a href=\"#H18\" id=\"outline-link-H18\">RECOMMENDATIONS OF OTHERS</a></li><li><a href=\"#H22846480\" id=\"outline-link-H22846480\">BLEEDING RISK</a></li><li><a href=\"#H3836021848\" id=\"outline-link-H3836021848\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H10159433\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H10157891\" id=\"outline-link-H10157891\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"CARD/101|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/75259\" class=\"graphic graphic_table\">- HAS-BLED bleeding risk score</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=antiplatelet-agents-in-acute-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Antiplatelet agents in acute ST elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antiplatelet-agents-in-acute-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">Antiplatelet agents in acute non-ST elevation acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antithrombotic-therapy-for-elective-percutaneous-coronary-intervention-general-use\" class=\"medical medical_review\">Antithrombotic therapy for elective percutaneous coronary intervention: General use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antithrombotic-therapy-for-prosthetic-heart-valves-indications\" class=\"medical medical_review\">Antithrombotic therapy for prosthetic heart valves: Indications</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antithrombotic-therapy-in-patients-with-heart-failure\" class=\"medical medical_review\">Antithrombotic therapy in patients with heart failure</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aspirin-for-the-secondary-prevention-of-atherosclerotic-cardiovascular-disease\" class=\"medical medical_review\">Aspirin for the secondary prevention of atherosclerotic cardiovascular disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=aspirin-exacerbated-respiratory-disease\" class=\"medical medical_review\">Aspirin-exacerbated respiratory disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=atrial-fibrillation-anticoagulant-therapy-to-prevent-embolization\" class=\"medical medical_review\">Atrial fibrillation: Anticoagulant therapy to prevent embolization</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-angiography-and-revascularization-for-unstable-angina-or-non-st-elevation-acute-myocardial-infarction\" class=\"medical medical_review\">Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=coronary-artery-disease-patients-requiring-combined-anticoagulant-and-antiplatelet-therapy\" class=\"medical medical_review\">Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=criteria-for-the-diagnosis-of-acute-myocardial-infarction\" class=\"medical medical_review\">Criteria for the diagnosis of acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-challenge-and-desensitization-protocols-for-nsaid-reactions\" class=\"medical medical_review\">Diagnostic challenge and desensitization protocols for NSAID reactions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects\" class=\"medical medical_review\">Direct oral anticoagulants and parenteral direct thrombin inhibitors: Dosing and adverse effects</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=left-ventricular-aneurysm-and-pseudoaneurysm-following-acute-myocardial-infarction\" class=\"medical medical_review\">Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=left-ventricular-thrombus-after-acute-myocardial-infarction\" class=\"medical medical_review\">Left ventricular thrombus after acute myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=long-term-antiplatelet-therapy-after-coronary-artery-stenting-in-stable-patients\" class=\"medical medical_review\">Long-term antiplatelet therapy after coronary artery stenting in stable patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-warfarin-associated-bleeding-or-supratherapeutic-inr\" class=\"medical medical_review\">Management of warfarin-associated bleeding or supratherapeutic INR</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nsaids-including-aspirin-allergic-and-pseudoallergic-reactions\" class=\"medical medical_review\">NSAIDs (including aspirin): Allergic and pseudoallergic reactions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-hemostasis\" class=\"medical medical_review\">Overview of hemostasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-st-elevation-myocardial-infarction\" class=\"medical medical_review\">Overview of the acute management of ST-elevation myocardial infarction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-acute-management-of-non-st-elevation-acute-coronary-syndromes\" class=\"medical medical_review\">Overview of the acute management of non-ST elevation acute coronary syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathology-and-pathogenesis-of-the-vulnerable-plaque\" class=\"medical medical_review\">Pathology and pathogenesis of the vulnerable plaque</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=warfarin-coumadin-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Warfarin (Coumadin) (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=primary-percutaneous-coronary-intervention-in-acute-st-elevation-myocardial-infarction-determinants-of-outcome\" class=\"medical medical_review\">Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-anticoagulation\" class=\"medical medical_society_guidelines\">Society guideline links: Anticoagulation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-non-st-elevation-acute-coronary-syndromes-non-st-elevation-myocardial-infarction\" class=\"medical medical_society_guidelines\">Society guideline links: Non-ST elevation acute coronary syndromes (non-ST elevation myocardial infarction)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-st-elevation-myocardial-infarction-stemi\" class=\"medical medical_society_guidelines\">Society guideline links: ST elevation myocardial infarction (STEMI)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thromboembolism-anticoagulation-after-initial-management\" class=\"medical medical_review\">Venous thromboembolism: Anticoagulation after initial management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=venous-thromboembolism-initiation-of-anticoagulation-first-10-days\" class=\"medical medical_review\">Venous thromboembolism: Initiation of anticoagulation (first 10 days)</a></li></ul></div></div>","javascript":null}